13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • JTJN OVARIAN

    Acronym: 

    JTJN OVARIAN

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Gynaecological
    Trial Type Treatment
    Phase Phase II Tumour Stream Ovarian
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Female Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Gynaecological
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Female
    Molecular Target
    Tumour Stream Ovarian
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    14D-MC-JTJN: A phase II study of rexasertib in platinum-resistant or refractory recurrent ovarian cancer.

    Lay Summary

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Ganessan Kichenadasse Recruiting